Because thrombotic events are uncommon, small trials lack power and a meta-analysis of small trials would be vulnerable to publication bias.
This is not uncommon in trials of anticancer agents and may be due to less than optimal statistical power and the impact of secondary therapies.
Although well conducted qualitative studies can support trial design and improve our understanding of the effects of complex interventions and the mechanisms through which changes occur, qualitative studies remain relatively uncommon alongside trials of complex interventions.
Although it is not uncommon for trials on falls to report a reduction in the rate of falls but no significant difference in the proportion of fallers, 41 42 43 this trial may have been underpowered for detecting a difference in the proportion of fallers, as our sample had a lower risk of falls than anticipated.
17, 18 Recently, PFS6m has been utilized as a new primary outcome measure in neurooncology because objective radiographic responses are uncommon in trials of new agents for recurrent malignant glioma, and because disease stabilization (radiographic or clinical) has been perceived as a valuable and treatment-specific outcome.
The availability of clinical trial data at the level of the individual patient is uncommon, especially where trials have consistently used several different assessment scales permitting analysis of the relationship between treatment success as measured by pain relief and work interference.
First, it is dangerous deaths are not uncommon in clinical trials involving CAR-T.
Adverse events were very uncommon in the trials of oral vitamin D, with the following incidence rates of hypercalcemia reported: 0.1% in the trial by Chapuy et al (1994) [25], 0.8% in the trial by Chapuy et al (2002) [27], and 0.1% in the trial by Law et al. [29]; whereas there were no adverse events in the trial by Flicker et al. [28].
It is not uncommon for clinical trials to exclude patients who may be predisposed to cancer.
Such an inflation is not uncommon in real trials (see the example given by Koch [ 10]).
However, missed and off-schedule visits are not uncommon in PMTCT trials.
